Therapeutic effect of sodium-glucose cotransporter type 2 inhibitors in acute heart failure
DOI:
https://doi.org/10.51481/amc.v65i4.1326Keywords:
sodium-glucose transporter 2 inhibitors, dapagliflozin, empagliflozin, canagliflozin, sotagliflozin, acute heart failureAbstract
Acute heart failure is an emergency that increases cardiovascular mortality due to symptoms and signs of vascular congestion and hypoperfusion. Current management with diuretics, inotropes, and vasopressors improves the clinical status; However, the morbidity and mortality associated with this pathology remains highly significant. On the other hand, sodium-glucose cotransporter 2 (SGLT2i) inhibitors have shown a reduction in hospitalization and cardiovascular mortality in patients with chronic heart failure. Therefore, the objective of this article is to analyze the clinical effects of this pharmacological group in acute heart failure, based on scientific research. The findings of these investigations demonstrated a clinical benefit of SGLT2i on this pathology, based on parameters such as mortality, hospitalization, clinical events, renal function, diuretic effect and concentrations of the NTproBnp biomarker, which will be detailed in this article. Therefore, it was concluded that these drugs are safe on the clinical course of acute heart failure.
Downloads
References
Arrigo M, Jessup M, Mullens W, Reza N, Shah AM, Sliwa K et al. Acute heart failure. Nat Rev Dis Primers. 2020;6:16. DOI: 10.1038/s41572-020-0151-7.
Kurmani S, Squire I. Acute Heart Failure: Definition, Classification and Epidemiology. Curr Heart Fail Rep.2017; 14:385-392. DOI: 10.1007/s11897-017-0351-y.
Raj L, Maidman SD, Adhyaru BB. Inpatient management of acute decompensated heart failure. Postgrad Med J. 2020;96:33-42. DOI: 10.1136/postgradmedj-2019-136742.
Bazmpani MA, Papanastasiou CA, Kamperidis V, Zebekakis PE, Karvounis H, Kalogeropoulos AP et al. Contemporary Data on the Status and Medical Management of Acute Heart Failure. Curr Cardiol Rep. 2022;24:2009-2022. DOI: 10.1007/s11886-022-01822-1.
Liu B, Wang Y, Zhang Y, Yan B. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction. Review Curr Top Med Chem. 2019;19:1818-1849. DOI: 10.2174/1568026619666190828161409.
Ferreira JP, Pimenta J, Moura B, Aguiar C, Franco F. Use of sodium glucose co-transporter 2 inhibitors in acute heart failure: a practical guidance. ESC Heart Fail. 2022;9:4344-4347. DOI: 10.1002/ehf2.14090.
McCallum W, Tighiouart H, Testani JM, Griffin M, Konstam MA, Udelson JE et al. Acute Kidney Function Declines in the Context of Decongestion in Acute Decompensated Heart Failure. JACC Heart Fail. 2020; 8:537-547. DOI: 10.1016/j.jchf.2020.03.009.
Griffin M, Riello R, Rao VS, Ivey-Miranda J, Fleming J, Maulion C, et al. Sodium glucose cotransporter 2 inhibitors as diuretic adjuvants in acute decompensated heart failure: a case series. ESC Heart Fail. 2020; 7:1966-1971. DOI: 10.1002/ehf2.12759.
Kim NH, Kim NH. Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics. Diabetes Metab J. 2022; 46:543-551. DOI: 10.4093/dmj.2022.0209.
Estrada AK, Delgado-Maldonado T, Lara-Ramírez EE, Martínez-Vázquez AV, Ortiz-Pérez E, Paz-González AD, et al. Recent Advances in the Development of Type 2 Sodium-Glucose Cotransporter Inhibitors for the Treatment of Type 2 Diabetes Mellitus. Mini Rev Med Chem. 2022; 22:586-599. DOI: 10.2174/1389557521666210805112416.
McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019; 381:1995-2008. DOI: 10.1056/NEJMoa1911303.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Acta Médica Costarricense
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)
